|
|
| Product Name: | RI-2 | | Synonyms: | RI-2;1-(3,4-Dichlorophenyl)-3-(4-methoxyphenyl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione;1H-Pyrrole-2,5-dione, 1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-(4-morpholinyl)-;RI2;RI 2;CS-1675;Inhibitor,RI 2,RAD51,inhibit,RI2,RI-2 | | CAS: | 1417162-36-7 | | MF: | C21H18Cl2N2O4 | | MW: | 433.28 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1417162-36-7.mol |  |
| Boiling point | 605.6±55.0 °C(Predicted) | | density | 1.441±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥21.65 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | | form | solid | | pka | -0.77±0.20(Predicted) | | color | Yellow to orange |
| Description | RI-2 is a reversible inhibitor of RAD51 (IC50 = 44.2 μM), a protein that is central to the homologous recombination process initiated upon DNA double-strand breaks and is often overexpressed in a wide range of human cancer cell types. At 150 μM, it has been shown to inhibit DNA repair and to sensitize cancer cells to cross-linking chemotherapy in vitro. | | Uses | RI-2 is a reversible inhibitor of RAD51 (IC50 = 44.2 μM), a protein that is central to the homologous recombination process initiated upon DNA double-strand breaks and is often overexpressed in a wide range of human cancer cell types. At 150 μM, it has been shown to inhibit DNA repair and to sensitize cancer cells to cross-linking chemotherapy in vitro.[Cayman Chemical] | | in vitro | although ri-2 did exhibit reduced activity relative to ri-1, it did retain enough activity to sensitize cells to mmc cell-based assays. ri-2 exhibited no reactivity toward glutathione after incubation for 24 hours. rad51 protein that had been treated with ri-2 prior to washing exhibited no measurable loss of dna binding activity, even though ri-2 is known to inhibit rad51 with an ic50 of 44.17 μm. this indicates that rad51 inhibition by ri-2 is fully reversible [1]. | | in vivo | ri-1, the analogue of ri-2, facilitated mapping of the binding pocket within known crystal structures of rad51. however, this reactivity of ri-1 potentially may limit its development in pre-clinical animal models. ri-1 has been found to exhibit a relatively short half-life, due to reactivity in thiol-containing solutions [1]. | | IC 50 | 44.17 μm | | references | [1] budke b, kalin jh, pawlowski m, zelivianskaia as, wu m, kozikowski ap, connell pp. an optimized rad51 inhibitor that disrupts homologous recombination without requiring michael acceptor reactivity. j med chem. 2013 jan 10;56(1):254-63. |
| | RI-2 Preparation Products And Raw materials |
|